⁦Candace Haddox, MD⁩ presenting SARC044 for patients with #GIST. Trial now open ⁦Dana-Farber⁩ #ctos

Tune in on Wednesday Nov 20 at 12:30pm GMT/7:30am ET to listen to our fireside chat at the #JefferiesHealthcare London conference. Register and join here bit.ly/4fwgI4I. Jefferies

Join us December 4th for our fireside chat at the 36th Annual Piper Sandler Healthcare Conference. The live webcast begins at 9:30 AM ET. Register and listen here: investors.cogentbio.com/events

We're in San Diego for #ASH24 & look forward to engaging w/the #hematology community & sharing updates w/bezuclastinib from APEX & SUMMIT. Find us at booth #2804 to learn more about our programs & our commitment to improving the lives of people w/#AdvSM #NonAdvSM #raredisease.

Today we reported positive updated clinical data from our ongoing Phase 2 APEX trial with bezuclastinib in #AdvSM. Read the update bit.ly/3D6oqEg and tune in to our webcast tomorrow morning at 8am ET/5am PT edge.media-server.com/mmc/p/g4z9xx79

Today's SUMMIT data highlight rapid & sustained symptomatic improvement in #NonAdvSM. We’re grateful to the patients, physicians & families who helped us complete enrollment ahead of schedule & look forward to topline results in July 2025. bit.ly/41mNQaH

Our CEO, Andrew Robbins, will present at #JPM25 on Tuesday, January 14th, at 7:30 am PT/10:30am ET. Tune in to the live webcast here bit.ly/427oSNa

This morning, we announced our 2025 planned milestones for bezuclastinib & our emerging research pipeline. With topline results expected from three registration-directed trials, 2025 is going to be transformational. Read more bit.ly/4hfGlr3

We're participating in the Guggenheim SMID Cap Biotech Conference next week. Listen to the analyst-led fireside discussion on Wednesday, February 5th at 9:30 a.m. ET. Register for the webcast here: bit.ly/427oSNa

Today we released our fourth quarter and full year financial results and recent business highlights and reiterated our anticipated milestones. Our progress in 2024 underscores the positive momentum we're carrying into 2025. Learn more here: bit.ly/41hAV8k

We recognized #CholangiocarcinomaAwarenessMonth by going green in sweatshirts from Cholangiocarcinoma Foundation. We're committed 2 supporting those affected by #cholangiocarcinoma & working w/groups like CCF to create change for this community by advancing science thru our FGFR program. #GreenforCCA

We’re excited 2 sponsor the Cholangiocarcinoma Foundation #CCFAnnualConference & grateful 2 be able 2 share our progress on our FGFR Clinical Program as we learn from leading experts, researchers & the #Cholangiocarcinoma Patient Community. Stop by the Cogent table 2 learn more. #ccfac25 #CCAhope

Proud to sponsor the SPAGN 2025 #SPAGN Annual Conference & support this important gathering of global patient advocates, researchers, & healthcare professionals coming together to improve outcomes for those living with sarcoma and #GIST #SarcomaAwareness #GISTAwareness

We were thrilled to present 4 preclinical posters at #AACR25. Thanks 2 all who came to chat as we shared updated results from our pipeline of potential best-in-class targeted therapies. Read our press release: bit.ly/4jUq1Nx & see our posters: bit.ly/3YWg369

Today we reported our first quarter 2025 financials. We’re looking forward to a data-rich year ahead with top-line results on track from our SUMMIT, APEX and PEAK trials. Read the full release here: bit.ly/3GI3dT1

Are you in Chicago for #ASCO25? Come find us in the Exhibit Hall at Booth 27165 to learn about our commitment to discover and develop potential best-in-class therapies for patients with genetically defined diseases. #NonAdvSM #GIST #AdvSM

Join us on Thursday at 7:35am ET for our presentation at the Jefferies Global Healthcare Conference. Register and listen in here: bit.ly/4kz93Va

Please note our new presentation time: 8:10am ET, Thursday, June 5 at the Jefferies Global Healthcare Conference. Register and listen in here: bit.ly/4kz93Va

We were thrilled to attend #EHA2025 and #EAACI2025!

Today we reported positive top-line results from Part 2 of our SUMMIT trial in #NonAdvSM achieving statistical significance across all primary & key 2ndary endpoints. Read the release: bit.ly/40Fqr39 Our webcast will begin at 8am ET. Join: bit.ly/4kmOYkJ